share_log

MannKind Corporation's (NASDAQ:MNKD) Institutional Investors Lost 3.9% Last Week but Have Benefitted From Longer-term Gains

MannKind Corporation's (NASDAQ:MNKD) Institutional Investors Lost 3.9% Last Week but Have Benefitted From Longer-term Gains

曼恩凱德生物醫療公司(納斯達克:MNKD)的機構投資者上週損失了3.9%,但從長期收益中受益。
Simply Wall St ·  2024/11/28 21:44

Key Insights

主要見解

  • Significantly high institutional ownership implies MannKind's stock price is sensitive to their trading actions
  • A total of 25 investors have a majority stake in the company with 44% ownership
  • Insiders have been selling lately
  • 顯著高的機構持股意味着曼恩凱德生物醫療的股票價格對其交易行爲非常敏感。
  • 共有25名投資者擁有該公司的多數股份,佔股44%。
  • 內部人員最近一直在賣出。

To get a sense of who is truly in control of MannKind Corporation (NASDAQ:MNKD), it is important to understand the ownership structure of the business. With 56% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).

要了解誰真正控制着曼恩凱德公司(納斯達克:MNKD),了解業務的所有權結構是非常重要的。機構以56%的股份擁有公司的最多股票。換句話說,該集團面臨着最大的上行潛力(或下行風險)。

Losing money on investments is something no shareholder enjoys, least of all institutional investors who saw their holdings value drop by 3.9% last week. However, the 87% one-year return to shareholders may have helped lessen their pain. But they would probably be wary of future losses.

投資虧損是所有股東都不喜歡的事情,尤其是那些上週其持股價值下降了3.9%的機構投資者。然而,87%的年度回報可能幫助減輕了他們的痛苦。但他們可能會對未來的損失感到警惕。

Let's delve deeper into each type of owner of MannKind, beginning with the chart below.

讓我們深入探討曼恩凱德生物醫療的每種所有者類型,從下面的圖表開始。

big
NasdaqGM:MNKD Ownership Breakdown November 28th 2024
納斯達克GM:MNKD 所有權結構 2024年11月28日

What Does The Institutional Ownership Tell Us About MannKind?

機構所有權告訴我們關於曼恩凱德生物醫療什麼?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見的指數回報進行比較。因此,他們通常會考慮購買包括在相關基準指數中的較大公司。

As you can see, institutional investors have a fair amount of stake in MannKind. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of MannKind, (below). Of course, keep in mind that there are other factors to consider, too.

正如您所看到的,機構投資者在曼恩凱德生物醫療中擁有相當數量的股份。這在職業投資者中顯示出了一定的可信度。但我們不能僅僅依賴這一事實,因爲機構有時也會做出錯誤的投資,就像其他人一樣。如果兩個大型機構投資者同時試圖出售某隻股票,股價大幅下跌並不罕見。因此,檢查曼恩凱德生物醫療過去的盈利軌跡是值得的(見下文)。當然,還要記住有其他因素需要考慮。

big
NasdaqGM:MNKD Earnings and Revenue Growth November 28th 2024
納斯達克GM:MNKD 2024年11月28日的營收和收益增長

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Hedge funds don't have many shares in MannKind. Our data shows that BlackRock, Inc. is the largest shareholder with 8.6% of shares outstanding. In comparison, the second and third largest shareholders hold about 5.7% and 3.5% of the stock. In addition, we found that Michael Castagna, the CEO has 0.8% of the shares allocated to their name.

投資者應該注意,機構實際上擁有公司的一半以上股份,因此他們可以集體擁有一定的權力。對沖基金在曼恩凱德生物醫療的股份並不多。我們的數據顯示,貝萊德公司是最大股東,持有8.6%的流通股。相比之下,第二和第三大股東分別持有約5.7%和3.5%的股票。此外,我們發現首席執行官邁克爾·卡斯塔尼亞持有其名下0.8%的股份。

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

對我們的所有權數據進行更深入的研究表明,前25名股東的持股總額不到註冊表的一半,表明有一個小股東的大群體,其中沒有單個股東擁有多數股份。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

儘管研究公司的機構持股可以增加您的研究價值,但研究分析師的建議也是一個好習慣,以更深入地了解股票的預期表現。有相當數量的分析師關注該股,因此了解他們對未來的總體觀點可能很有用。

Insider Ownership Of MannKind

曼恩凱德生物醫療的內部持股

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

雖然內部人員的具體定義可能是主觀的,但幾乎所有人都認爲董事會成員是內部人員。公司管理層應向董事會回答問題,後者應代表股東的利益。值得注意的是,有時高層管理人員也會成爲董事會成員。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。

Our most recent data indicates that insiders own some shares in MannKind Corporation. It is a pretty big company, so it is generally a positive to see some potentially meaningful alignment. In this case, they own around US$40m worth of shares (at current prices). If you would like to explore the question of insider alignment, you can click here to see if insiders have been buying or selling.

我們最近的數據表明,內部人士持有曼恩凱德生物醫療的部分股票。 這是一家相當大的公司,因此看到一些潛在的有意義的對齊通常是積極的。在這種情況下,他們持有約4000萬美元的股票(按當前價格計算)。如果您想探索內部人士對齊的問題,可以點擊這裏查看內部人士是否有買入或賣出的行爲。

General Public Ownership

一般大衆所有權

With a 42% ownership, the general public, mostly comprising of individual investors, have some degree of sway over MannKind. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

公衆持有42%的股份,大多數是個人投資者,對曼恩凱德生物醫療有一定程度的影響。雖然這種持股規模相當可觀,但如果決策與其他大股東不一致,可能不足以改變公司政策。

Next Steps:

下一步:

It's always worth thinking about the different groups who own shares in a company. But to understand MannKind better, we need to consider many other factors. Case in point: We've spotted 4 warning signs for MannKind you should be aware of, and 2 of them are a bit unpleasant.

考慮不同的股東群體總是值得的。但要更好地理解曼恩凱德生物醫療,我們需要考慮許多其他因素。 例如:我們發現曼恩凱德生物醫療有4個警告信號你應該注意,其中2個信號有點不愉快。

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

如果您希望了解分析師在未來增長方面的預測,請務必不要錯過這份免費報告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論